4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
|
|
|
- CAS号:
- 892711-75-0
- 英文名:
- CDN 1163
- 英文别名:
- CDN1163;4-isopropoxy-N-(2-methylquinolin-8-yl)benzamide;N-(2-methylquinolin-8-yl)-4-propan-2-yloxybenzamide;4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide;Benzamide, 4-(1-methylethoxy)-N-(2-methyl-8-quinolinyl)-;Inhibitor,CDN 1163,Calcium Channel,Ca channels,Ca2+ channels,CDN-1163,CDN1163,inhibit
- 中文名:
- 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
- 中文别名:
- 化合物CDN1163;CDN 1163,SERCA2变构激活剂;4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
- CBNumber:
- CB92722925
- 分子式:
- C20H20N2O2
- 分子量:
- 320.39
- MOL File:
- 892711-75-0.mol
|
|
|
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺化学性质
-
熔点:
-
87 - 89°C
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
Soluble in DMSO (>25 mg/ml)
-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to beige
-
|
-
稳定性:
-
Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
-
|
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺性质、用途与生产工艺
CDN1163是一种 sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 的小分子变构激活剂，可改善 Ca2+ 稳态。
CDN1163 (5.5-25 mM; 0-8 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner.
Western Blot Analysis
|
Cell Line:
|
Rat cardiac myocyte cells (H9c2)
|
|
Concentration:
|
5.5 mM, 25 mM
|
|
Incubation Time:
|
0 hour, 4 hours, 8 hours
|
|
Result:
|
High glucose-induced resistin and nuclear NFATc expression were significantly reduced. The phosphorylation of AMPKα is increased in a time-dependent manner.
|
CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male
ob/ob
mice and lean
ob/+
mice) increases SERCA2 Ca
2+
-ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca
2+
transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in
ob/ob
mice in vivo.
|
Animal Model:
|
Male 8-10-week old
ob/ob
mice and lean
ob/+
mice
|
|
Dosage:
|
50 mg/kg
|
|
Administration:
|
Intraperitoneal injection; for 5 days
|
|
Result:
|
Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.
|
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/01/25 | HY-101455 | CDN1163 | | 1 mg | 350元 |
| 2024/01/25 | HY-101455 | 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
CDN1163 | 892711-75-0 | 5mg | 770元 |
4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
生产厂家
892711-75-0, 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺 相关搜索:
- 药靶配体
- 抑制剂
- CDN 1163,SERCA2变构激活剂
- 化合物CDN1163
- 4-异丙氧基-N-(2-甲基喹啉-8-基)苯甲酰胺
- 892711-75-0
- Inhibitor,CDN 1163,Calcium Channel,Ca channels,Ca2+ channels,CDN-1163,CDN1163,inhibit
- Benzamide, 4-(1-methylethoxy)-N-(2-methyl-8-quinolinyl)-
- 4-(1-Methylethoxy)-N-(2-methyl-8-quinolinyl)benzamide
- N-(2-methylquinolin-8-yl)-4-propan-2-yloxybenzamide
- CDN1163
- 4-isopropoxy-N-(2-methylquinolin-8-yl)benzamide